Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
about
A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.State of the art - how I manage immune thrombocytopenia.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).
P2860
Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@ast
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@en
type
label
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@ast
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@en
prefLabel
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@ast
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of rituxim ...... adult immune thrombocytopenia.
@en
P2093
Françoise Roudot-Thoraval
Jean-Marc Durand
Laurent Chiche
Marc Michel
Matthieu Mahévas
Medhi Khellaf
Mikael Ebbo
Nicolas Schleinitz
Philippe Bierling
P2860
P304
P356
10.1002/AJH.23518
P577
2013-09-03T00:00:00Z